Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.
JCR Pharmaceuticals has announced a leadership transition effective April 1, 2026, marking a generational shift as the company celebrates its 50th anniversary. Toru Ashida will become Chairman and Hiroyuki Sonoda will assume the role of President, while current Chairman, President, and CEO Shin Ashida will transition to Founder and Director. This change aims to strengthen the management structure and enhance long-term corporate value.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a biopharmaceutical company based in Hyogo, Japan, focused on innovation in biopharmaceutical research and manufacturing. The company is known for its commitment to advancing healthcare solutions and has been a significant player in the industry since its founding in 1975.
Average Trading Volume: 652,898
Technical Sentiment Signal: Sell
Current Market Cap: Yen58.29B
Find detailed analytics on 4552 stock on TipRanks’ Stock Analysis page.